Aprepitant API Manufacturers & Suppliers

Aprepitant (CAS 170729-80-3) is an NK1 receptor antagonist used as part of combination antiemetic regimens for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy, including high‑dose cisplatin. It belongs to the phenylmorpholine class, characterized by a morpholine ring linked to an aromatic benzene system.

Its clinical utility is based on selective, high‑affinity antagonism of human NK1 receptors, which are activated by substance P. Aprepitant shows minimal affinity for serotonin 5‑HT3, dopamine, or corticosteroid receptors. Through central blockade of NK1 receptors, it modulates emetic signaling pathways that are distinct from those targeted by 5‑HT3 antagonists and corticosteroids, enabling additive or synergistic effects when co‑administered with agents such as ondansetron and dexamethasone.

Aprepitant crosses the blood–brain barrier, as demonstrated in animal studies and human PET imaging, with measurable NK1 receptor occupancy in the central nervous system. In preclinical and clinical settings, it inhibits both the early and delayed phases of chemotherapy‑induced emesis triggered by cytotoxic agents. It is an approved antiemetic globally and has also been explored in investigational contexts.

Aprepitant is absorbed orally, undergoes extensive hepatic metabolism, and is a substrate, inhibitor, and inducer of multiple cytochrome P450 enzymes, particularly CYP3A4. These interactions influence exposure profiles and necessitate attention to co‑administered therapies metabolized through the same pathways. The compound’s safety considerations include potential drug–drug interactions, effects on corticosteroid levels when given concurrently, and monitoring in populations with hepatic impairment.

Aprepitant is marketed in various regions as single‑agent capsules or as part of combination antiemetic packs.

For API procurement, sourcing should prioritize manufacturers with demonstrated control of stereochemistry, impurity profile, and polymorphic form, along with full regulatory documentation and compliance with ICH and regional GMP expectations.